MedTrace Logo

Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.

NCT00383864 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2006-10-06

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation. The only approved drugs for treatment of hepatitis C are pegylated interferon and ribavirin.

Conditions

  • Hepatitis C

Interventions

DRUG

Pegylated interferon and ribavirin

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Xavier Forns, MD · Liver Unit, Hospital Clinic, Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Completion
2006-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383864 on ClinicalTrials.gov